Quote | Legend Biotech Corporation (NASDAQ:LEGN)
Last: | $40.01 |
---|---|
Change Percent: | -0.48% |
Open: | $43.54 |
Close: | $40.01 |
High: | $45.03 |
Low: | $39.88 |
Volume: | 3,381,970 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | Legend Biotech Corporation (NASDAQ:LEGN)
2024-05-31 07:30:07 ET Citigroup analyst issues BUY recommendation for LEGN on May 31, 2024 05:30AM ET. The previous analyst recommendation was Buy. LEGN was trading at $43.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6,...
Message Board Posts | Legend Biotech Corporation (NASDAQ:LEGN)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
2024-05-31 07:30:07 ET Citigroup analyst issues BUY recommendation for LEGN on May 31, 2024 05:30AM ET. The previous analyst recommendation was Buy. LEGN was trading at $43.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6,...
First disclosure from Cohort D of the Phase 2 CARTITUDE-2 study investigating CARVYKTI ® in patients who had suboptimal response to frontline ASCT in an oral presentation at ASCO & EHA An oral presentation at ASCO of data from the Phase 3 CARTITUDE-4 study evaluating CARVYKTI...